Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes.
Platelet activation is a critical mechanism in acute coronary artery syndromes and ischemic complications of percutaneous coronary revascularization. Thrombin and platelet inhibition are the current mainstays of therapy for these problems. Inhibitors of platelet GP IIb-IIIa, the final common pathway of platelet aggregation, have recently undergone clinical evaluation as therapeutics for acute ischemic syndromes, and as adjuvants for percutaneous revascularization. The results of these prospective, controlled trials, and current evaluations of GP IIb-IIIa inhibitors are summarized in this review.
Kugelmass
A D
AD
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA.
D000208:Acute Disease; D002986:Clinical Trials as Topic; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex